α-Synuclein increases β-amyloid secretion by promoting β-/γ-secretase processing of APP

PLoS ONE

Volumn 12, Issue 2, 2017, Pages

  Roberts, Hazel L ^a   Schneider, Bernard L ^b   Brown, David R ^a  

^a University of Bath   (United Kingdom)

^b EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; BETA SECRETASE 1; GAMMA SECRETASE; PHOSPHATIDYLINOSITOL 3 KINASE; TAU PROTEIN; THYMIDINE KINASE; IRON; ONCOPROTEIN; SECRETASE; TSAP6 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL DENSITY; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; ELECTROPHORESIS; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IRON CHELATION; LUCIFERASE ASSAY; NONHUMAN; OPTICAL DENSITY; OXIDATIVE STRESS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; UPREGULATION; WESTERN BLOTTING; ANIMAL; GENETICS; METABOLISM; MUTATION; NERVE CELL; PROTEIN DEGRADATION; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; IRON; MUTATION; NEURONS; ONCOGENE PROTEINS; OXIDATIVE STRESS; PROTEOLYSIS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 85012141228     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0171925     Document Type: Article

References (93)

1. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ. α-Synuclein in Lewy bodies. Nature. 1997; 388: 839-840. doi: 10.1038/42166 PMID: 9278044
2. Goldgaber D, Lerman M, McBride OW, Saffiotti U, Gajdusek DC. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer' s disease. Science. 1987; 235: 877-880. PMID: 3810169
3. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987. pp. 733-736. doi: 10.1038/325733a0 PMID: 2881207
4. Tanzi R, Gusella JF, Watkins PC, Bruns GAP, St George-Hyslop P, Van Keuren ML, et al. Amyloid β protein gene: cDNA, mRNA distributon, and genetic linkage near the Alzheimer locus. Science. 1987; 235: 880-884. PMID: 2949367
5. Kosik KS, Orecchio LD, Binder L, Trojanowski JQ, Lee VM-Y, Lee G. Epitopes that span the tau molecule are shared with paired helical filaments. Neuron. 1988; 1: 817-825. PMID: 2483104
6. Jellinger KA. α-Synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution-a pilot study. Acta Neuropathol. 2003; 106: 191-201. doi: 10.1007/s00401-003-0725-y PMID: 12845452
7. Schneider JA, Aggarwala NT, Barnesa L, Boylea P, Bennett DA. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimer's Dis. 2009; 18: 691-701.
8. Uchikado H, Lin W-L, DeLucia MW, Dickson DW. Alzheimer disease with amygdala Lewy bodies: a distinct form of α-synucleinopathy. J Neuropathol Exp Neurol. 2006; 65: 685-97. doi: 10.1097/01.jnen. 0000225908.90052.07 PMID: 16825955
9. Ringman JM, Monsell S, Ng DW, Zhou Y, Nguyen A, Coppola G, et al. Neuropathology of autosomal dominant Alzheimer disease in the National Alzheimer Coordinating Center database. J Neuropathol Exp Neurol. 2016; 75: 284-290. doi: 10.1093/jnen/nlv028 PMID: 26888304
10. Parkkinen L, Soininen H, Alafuzoff I. Regional distribution of α-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol. 2003; 62: 363-367. PMID: 12722828
11. Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using α-synuclein immunohistochemistry. Brain Pathol. 2000; 10: 378-384. PMID: 10885656
12. Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Deerlin V Van, et al. Neuropathologic substrates of Parkinson's disease dementia. Ann Neurol. 2012; 72: 587-598. doi: 10.1002/ana.23659 PMID: 23037886
13. Lashley T, Holton JL, Gray E, Kirkham K, Oapos;Sullivan SS, Hilbig A, et al. Cortical α-synuclein load is associated with amyloid-β plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol. 2008; 115: 417-425. doi: 10.1007/s00401-007-0336-0 PMID: 18185940
14. Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, et al. Aβ deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseases. Neurobiol Aging. 2005; 26: 1183-92. doi: 10.1016/j.neurobiolaging.2004.10.006 PMID: 15917102
15. Marsh SE, Blurton-Jones M. Examining the mechanisms that link β-amyloid and α-synuclein pathologies. Alzheimers Res Ther. 2012; 4: 11. doi: 10.1186/alzrt109 PMID: 22546279
16. Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease. Park Relat Disord. 2015; 21: 758-764.
17. Vranová HP, Hényková E, Kaiserová M, Menšíková K, Vaštík M, Mareš J, et al. Tau protein, beta-amyloid1-42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. J Neurol Sci. 2014; 343: 120-124. doi: 10.1016/j.jns.2014.05.052 PMID: 24928081
18. Hall S, Surova Y, Öhrfelt A, Zetterberg H, Lindqvist D, Hansson O. CSF biomarkers and clinical progression of Parkinson disease. Neurology. 2015; 84: 57-63. doi: 10.1212/WNL.0000000000001098 PMID: 25411441
19. Skogseth RE, Bronnick K, Pereira JB, Mollenhauer B, Weintraub D, Fladby T, et al. Associations between cerebrospinal fluid biomarkers and cognition in early untreated Parkinson's Disease. J Parkinsons Dis. 2015; 5: 783-792. doi: 10.3233/JPD-150682 PMID: 26599300
20. Terrelonge M, Marder KS, Weintraub D, Alcalay RN. CSF β-amyloid 1-42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease. J Mol Neurosci. 2015; 58: 88-92. doi: 10. 1007/s12031-015-0647-x PMID: 26330275
21. Alves G, Lange J, Blennow K, Zetterberg H, Andreasson U, Førland MG, et al. CSF Aβ42 predicts early-onset dementia in Parkinson disease. Neurology. 2014; 82: 1784-1790. doi: 10.1212/WNL. 0000000000000425 PMID: 24748671
22. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007; 22: 1689-1707. doi: 10.1002/mds. 21507 PMID: 17542011
23. Bate C, Gentleman S, Williams A. α-Synuclein induced synapse damage is enhanced by amyloid-β1-42. Mol Neurodegener. 2010; 5: 55. doi: 10.1186/1750-1326-5-55 PMID: 21138585
24. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, et al. β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. PNAS. 2001; 98: 12245-12250. doi: 10.1073/pnas.211412398 PMID: 11572944
25. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic interactions between Aβ, tau, and α-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010; 30: 7281-9. doi: 10.1523/JNEUROSCI.0490-10.2010 PMID: 20505094
26. Ono K, Takahashi R, Ikeda T, Yamada M. Cross-seeding effects of amyloid β-protein and α synuclein. J Neurochem. 2012; 122: 883-890. doi: 10.1111/j.1471-4159.2012.07847.x PMID: 22734715
27. Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R. Interaction between Aβ peptide and α-synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res. 2006; 31: 1153-1162. doi: 10.1007/s11064-006-9140-9 PMID: 16947080
28. Atsmon-Raz Y, Miller Y. Non-amyloid-β component of human α-synuclein oligomers induces formation of new Aβ oligomers: insight into the mechanisms that link Parkinson's and Alzheimer's diseases. ACS Chem Neurosci. 2015; 7: 46-55. doi: 10.1021/acschemneuro.5b00204 PMID: 26479553
29. Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, et al. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One. 2008; 3: e3135. doi: 10.1371/journal.pone.0003135 PMID: 18769546
30. Bachhuber T, Katzmarski N, McCarter JF, Loreth D, Tahirovic S, Kamp F, et al. Inhibition of amyloid-β plaque formation by α-synuclein. Nat Med. 2015; 21: 802-7. doi: 10.1038/nm.3885 PMID: 26099047
31. Kallhoff V, Peethumnongsin E, Zheng H. Lack of α-synuclein increases amyloid plaque accumulation in a transgenic mouse model of Alzheimer's disease. Mol Neurodegener. 2007; 2: 6. doi: 10.1186/1750-1326-2-6 PMID: 17367539
32. Kazmierczak A, Strosznajder JB, Adamczyk A. α-Synuclein enhances secretion and toxicity of amyloid beta peptides in PC12 cells. Neurochem Int. 2008; 53: 263-269. doi: 10.1016/j.neuint.2008.08.004 PMID: 18804502
33. Majd S, Chegini F, Chataway T, Zhou X-F, Gai W. Reciprocal induction between α-synuclein and β-amyloid in adult rat neurons. Neurotox Res. 2013; 23: 69-78. doi: 10.1007/s12640-012-9330-y PMID: 22610785
34. Zhang H, Ma Q, Zhang Y, Xu H. Proteolytic processing of Alzheimer's β-amyloid precursor protein. J Neurochem. 2012; 120: 9-21. doi: 10.1111/j.1471-4159.2011.07519.x PMID: 22122372
35. Jo D, Arumugam T V, Woo H, Park J, Mughal M, Hyun D, et al. Evidence that γ secretase mediates oxidative stress-induced β-secretase expression in Alzheimer's disease. Neurobiol Aging. 2010; 31: 917-925. doi: 10.1016/j.neurobiolaging.2008.07.003 PMID: 18687504
36. Tamagno E, Guglielmotto M, Aragno M, Borghi R, Giliberto L, Muraca G, et al. Oxidative stress activates a positive feedback between the β- and γ-secretase cleavages of the β-amyloid precursor protein. J Neurochem. 2008; 104: 683-695. doi: 10.1111/j.1471-4159.2007.05072.x PMID: 18005001
37. Marwarha G, Raza S, Prasanthi JRP, Ghribi O. Gadd153 and NF-κB crosstalk regulates 27-hydroxycholesterol-induced increase in BACE1 and β-amyloid production in human neuroblastoma SH-SY5Y cells. PLoS One. 2013; 8: e70773. doi: 10.1371/journal.pone.0070773 PMID: 23951005
38. Mouton-Liger F, Paquet C, Dumurgier J, Bouras C, Pradier L, Gray F, et al. Oxidative stress increases BACE1 protein levels through activation of the PKR-eIF2α pathway. Biochim Biophys Acta. 2012; 1822: 885-896. doi: 10.1016/j.bbadis.2012.01.009 PMID: 22306812
39. Tan J-L, Li Q-X, Ciccotosto GD, Crouch PJ, Culvenor JG, White AR, et al. Mild oxidative stress induces redistribution of BACE1 in non-apoptotic conditions and promotes the amyloidogenic processing of Alzheimer's disease amyloid precursor protein. PLoS One. 2013; 8: e61246. doi: 10.1371/journal.pone. 0061246 PMID: 23613819
40. Chami L, Checler F. BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and beta-amyloid production in Alzheimer's disease. Mol Neurodegener. 2012; 7: 52. doi: 10.1186/1750-1326-7-52 PMID: 23039869
41. Oda A, Tamaoka A, Araki W. Oxidative stress up-regulates presenilin 1 in lipid rafts in neuronal cells. J Neurosci Res. 2010; 88: 1137-1145. doi: 10.1002/jnr.22271 PMID: 19885829
42. Guo C, Wang T, Zheng W, Shan ZY, Teng WP, Wang ZY. Intranasal deferoxamine reverses ironinduced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging. 2013; 34: 562-575. doi: 10.1016/j.neurobiolaging.2012.05.009 PMID: 22717236
43. Guo LY, Alekseev O, Li Y, Song Y, Dunaief JL. Iron increases APP translation and amyloid-beta production in the retina. Exp Eye Res. 2014; 129: 31-37. doi: 10.1016/j.exer.2014.10.012 PMID: 25456519
44. Kim CH, Yoo YM. Altered APP carboxyl-terminal processing under ferrous iron treatment in PC12 cells. Korean J Physiol Pharmacol. 2013; 17: 189-195. doi: 10.4196/kjpp.2013.17.3.189 PMID: 23776394
45. Davies P, Moualla D, Brown DR. Alpha-synuclein is a cellular ferrireductase. PLoS One. 2011; 6: e15814. doi: 10.1371/journal.pone.0015814 PMID: 21249223
46. Brown DR. α-Synuclein as a ferrireductase. Biochem Soc Trans. 2013; 41: 1513-7. doi: 10.1042/BST20130130 PMID: 24256246
47. Nakamura K. α-Synuclein and mitochondria: partners in crime? Neurotherapeutics. 2013; 10: 391-9. doi: 10.1007/s13311-013-0182-9 PMID: 23512373
48. Wang X, Moualla D, Wright JA, Brown DR. Copper binding regulates intracellular alpha-synuclein localisation, aggregation and toxicity. J Neurochem. 2010; 113: 704-14. doi: 10.1111/j.1471-4159.2010. 06638.x PMID: 20141569
49. Wright JA, McHugh PC, Pan S, Cunningham A, Brown DR. Counter-regulation of alpha- and beta-synuclein expression at the transcriptional level. Mol Cell Neurosci. 2013; 57: 33-41. doi: 10.1016/j.mcn. 2013.09.002 PMID: 24080388
50. Lau K-F, McLoughlin DM, Standen C, Irving NG, Miller CCJ. Fe65 and X11β co-localize with and compete for binding to the amyloid precursor protein. Mol Neurosci. 2000; 11: 3607-10.
51. Cox CJ, Choudhry F, Peacey E, Perkinton MS, Richardson JC, Howlett DR, et al. Dietary (-)-epicatechin as a potent inhibitor of βγ-secretase amyloid precursor protein processing. Neurobiol Aging. 2014; 31: 178-87.
52. Hoey SE, Williams RJ, Perkinton MS. Synaptic NMDA receptor activation stimulates α-secretase amyloid precursor protein processing and inhibits amyloid-β production. J Neurosci. 2009; 29: 4442-4460. doi: 10.1523/JNEUROSCI.6017-08.2009 PMID: 19357271
53. McHugh PC, Wright JA, Williams RJ, Brown DR. Prion protein expression alters APP cleavage without interaction with BACE-1. Neurochem Int. 2012; 61: 672-80. doi: 10.1016/j.neuint.2012.07.002 PMID: 22796214
54. Gaugler MN, Genc O, Bobela W, Mohanna S, Ardah MT, El-Agnaf OM, et al. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta Neuropathol. 2012; 123: 653-669. doi: 10.1007/s00401-012-0963-y PMID: 22361813
55. Azeredo da Silveira S, Schneider BL, Cifuentes-Diaz C, Sage D, Abbas-Terki T, Iwatsubo T, et al. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum Mol Genet. 2009; 18: 872-87. doi: 10.1093/hmg/ddn417 PMID: 19074459
56. Pino E, Amamoto R, Zheng L, Cacquevel M, Sarria JC, Knott GW, et al. FOXO3 determines the accumulation of α-synuclein and controls the fate of dopaminergic neurons in the substantia nigra. Hum Mol Genet. 2014; 23: 1435-52. doi: 10.1093/hmg/ddt530 PMID: 24158851
57. O'Connor T, Sadleir KR, Maus E, Velliquette RA, Zhao J, Cole SL, et al. Phosphorylation of the translation initiation factor eIF2α increases BACE1 levels and promotes amyloidogenesis. Neuron. 2008; 60: 988-1009. doi: 10.1016/j.neuron.2008.10.047 PMID: 19109907
58. Conway KA, Lee S, Rochet J, Ding TT, Williamson RE, Lansbury PT. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. PNAS. 2000; 97: 571-576. PMID: 10639120
59. Lázaro DF, Rodrigues EF, Langohr R, Shahpasandzadeh H, Ribeiro T, Guerreiro P, et al. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. PLoS Genet. 2014; 10: e1004741. doi: 10.1371/journal.pgen.1004741 PMID: 25393002
60. Burré J, Sharma M, Südhof TC. Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities. J Neurosci. 2012; 32: 15227-42. doi: 10. 1523/JNEUROSCI.3545-12.2012 PMID: 23100443
61. Robotta M, Hintze C, Schildknecht S, Zijlstra N, Jüngst C, Karreman C, et al. Locally resolved membrane binding affinity of the N-terminus of α-synuclein. Biochemistry. 2012; 51: 3960-3962. doi: 10. 1021/bi300357a PMID: 22494024
62. Vamvaca K, Volles MJ, Lansbury PT. The first N-terminal amino acids of α-synuclein are essential for α-helical structure formation in vitro and membrane binding in yeast. J Mol Biol. 2009; 389: 413-424. doi: 10.1016/j.jmb.2009.03.021 PMID: 19285989
63. Vamvaca K, Lansbury PT, Stefanis L. N-terminal deletion does not affect α-synuclein membrane binding, self-association and toxicity in human neuroblastoma cells, unlike yeast. J Neurochem. 2011; 119: 389-397. doi: 10.1111/j.1471-4159.2011.07431.x PMID: 21848810
64. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002; 4: 160-164. doi: 10.1038/ncb748 PMID: 11813001
65. Chen L, Feany MB. α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci. 2005; 8: 657-663. doi: 10.1038/nn1443 PMID: 15834418
66. Febbraro F, Sahin G, Farran A, Soares S, Jensen PH, Kirik D, et al. Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease. Neurobiol Dis. 2013; 56: 47-58. doi: 10.1016/j.nbd.2013.03.014 PMID: 23567651
67. Kragh CL, Lund LB, Febbraro F, Hansen HD, Gai W-P, El-Agnaf O, et al. α-Synuclein aggregation and ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem. 2009; 284: 10211-22. doi: 10.1074/jbc.M809671200 PMID: 19203998
68. Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, et al. The phosphorylation state of Ser-129 in human α-synuclein determines neurodegeneration in a rat model of Parkinson disease. PNAS. 2008; 105: 763-8. doi: 10.1073/pnas.0711053105 PMID: 18178617
69. Kuwahara T, Tonegawa R, Ito G, Mitani S, Iwatsubo T. Phosphorylation of α-synuclein protein at Ser-129 reduces neuronal dysfunction by lowering its membrane binding property in Caenorhabditis elegans. J Biol Chem. 2012; 287: 7098-109. doi: 10.1074/jbc.M111.237131 PMID: 22232559
70. McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, et al. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J Neuropathol Exp Neurol. 2009; 68: 515-524. doi: 10.1097/NEN.0b013e3181a24b53 PMID: 19525899
71. Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S, et al. Authentically phosphorylated α-synuclein at ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J Neurosci. 2011; 31: 16884-16894. doi: 10.1523/JNEUROSCI.3967-11.2011 PMID: 22090514
72. Oueslati A. Implication of alpha-synuclein phosphorylation at S129 in synucleinopathies: what have we learned in the last decade? J Parkinsons Dis. 2016; 6: 39-51. doi: 10.3233/JPD-160779 PMID: 27003784
73. Oueslati A, Schneider BL, Aebischer P, Lashuel HA. Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo. PNAS. 2013; 110: e3945-54. doi: 10.1073/pnas.1309991110 PMID: 23983262
74. Tenreiro S, Reimão-Pinto MM, Antas P, Rino J, Wawrzycka D, Macedo D, et al. Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease. PLoS Genet. 2014; 10: e1004302. doi: 10.1371/journal.pgen.1004302 PMID: 24810576
75. McFarland MA, Ellis CE, Markey SP, Nussbaum RL. Proteomics analysis identifies phosphorylationdependent α-synuclein protein interactions. Mol Cell Proteomics. 2008; 7: 2123-2137. doi: 10.1074/mcp.M800116-MCP200 PMID: 18614564
76. Yin G, Lopes da Fonseca T, Eisbach SE, Anduaga AM, Breda C, Orcellet ML, et al. α-Synuclein interacts with the switch region of Rab8a in a ser129 phosphorylation-dependent manner. Neurobiol Dis. 2014; 70: 149-61. doi: 10.1016/j.nbd.2014.06.018 PMID: 24983211
77. Fanutza T, Del Prete D, Ford MJ, Castillo PE, D'Adamio L. APP and APLP2 interact with the synaptic release machinery and facilitate transmitter release at hippocampal synapses. Elife. 2015; 4: e09743. doi: 10.7554/eLife.09743 PMID: 26551565
78. Laûek M, Weingarten J, Einsfelder U, Brendel P, Müller U, Volknandt W. Amyloid precursor proteins are constituents of the presynaptic active zone. J Neurochem. 2013; 127: 48-56. doi: 10.1111/jnc. 12358 PMID: 23815291
79. Groemer TW, Thiel CS, Holt M, Riedel D, Hua Y, Hüve J, et al. Amyloid precursor protein is trafficked and secreted via synaptic vesicles. PLoS One. 2011; 6: e18754. doi: 10.1371/journal.pone.0018754 PMID: 21556148
80. Oaks AW, Marsh-Armstrong N, Jones JM, Credle JJ, Sidhu A. Synucleins antagonize endoplasmic reticulum function to modulate dopamine transporter trafficking. PLoS One. 2013; 8: e70872. doi: 10. 1371/journal.pone.0070872 PMID: 23967127
81. Thayanidhi N, Helm JR, Nycz DC, Bentley M, Liang Y, Hay JC. α-Synuclein delays Endoplasmic Reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol Biol Cell. 2010; 21: 1850-1863. doi: 10.1091/mbc.E09-09-0801 PMID: 20392839
82. Zhou X, Li Y, Shi X, Ma C. An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: Targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels. Am J Transl Res. 2016; 8: 246-269. PMID: 27158324
83. Sambamurti K, Kinsey R, Maloney B, Ge Y, Lahiri DK, Genetics M. Gene structure and organization of the human β-secretase (BACE) promoter. FASEB J. 2004; 26: 1-26.
84. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, et al. Nonsteroidal antiinflammatory drugs repress β-secretase gene promoter activity by the activation of PPARγ. PNAS. 2006; 103: 443-448. doi: 10.1073/pnas.0503839103 PMID: 16407166
85. Mei Z, Yan P, Tan X, Zheng S, Situ B. Transcriptional regulation of BACE1 by NFAT3 leads to enhanced amyloidogenic processing. Neurochem Res. 2015; 40: 829-836. doi: 10.1007/s11064-015-1533-1 PMID: 25663301
86. ILL-Raga G, Palomer E, Wozniak MA, Ramos-Fernández E, Bosch-Morató M, Tajes M, et al. Activation of PKR causes amyloid β-peptide accumulation via de-repression of BACE1 expression. PLoS One. 2011; 6: e21456. doi: 10.1371/journal.pone.0021456 PMID: 21738672
87. Cho H-H, Cahill CM, Vanderburg CR, Scherzer CR, Wang B, Huang X, et al. Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. J Biol Chem. 2010; 285: 31217-32. doi: 10.1074/jbc.M110.149161 PMID: 20558735
88. Parihar MS, Parihar A, Fujita M, Hashimoto M, Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci. 2008; 65: 1272-84. doi: 10.1007/s00018-008-7589-1 PMID: 18322646
89. Bender A, Desplats P, Spencer B, Rockenstein E, Adame A, Elstner M, et al. TOM40 mediates mitochondrial dysfunction induced by α-synuclein accumulation in Parkinson's disease. PLoS One. 2013; 8: e62277. doi: 10.1371/journal.pone.0062277 PMID: 23626796
90. Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, et al. α-Synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol. 2000; 157: 401-410. PMID: 10934145
91. Petrou M, Dwamena BA, Foerster BR, Maceachern MP, Bohnen NI, Müller MLTM, et al. Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Mov Disord. 2015; 30: 928-935. doi: 10.1002/mds.26191 PMID: 25879534
92. Vann Jones SA, O'Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2014; 44: 673-83. doi: 10.1017/S0033291713000494 PMID: 23521899
93. George S, Brundin P. Immunotherapy in Parkinson's disease: Micromanaging alpha-synuclein aggregation. J Parkinsons Dis. 2015; 5: 413-424. doi: 10.3233/JPD-150630 PMID: 26406122